Pneumagen announce positive results from Phase 2 Proof of Concept Study

Oct 2023

Equity Gap Investee company PNEUMAGEN LIMITED has announced positive results from its Phase 2 Proof of Concept study. Following the administration of Neumifil, an intranasal drug to prevent and treat viral respiratory tract infections, patients challenged with influenza virus saw a significant reduction in both symptomatic infection rate and severity.

As it advances Neumifil into further clinical studies, Pneumagen marks a step closer to transforming the lives of patients suffering from viral respiratory tract infections.

Categorised as 2023